ResearchMoz | Cardiovascular Disorders Drug Development Pipeline Review, 2017

Researchmoz added Most up-to-date research on "ResearchMoz | Cardiovascular Disorders Drug Development Pipeline Review, 2017" to its huge collection of research reports.

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1049123

The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

• Which companies are the most active within the pipeline for CVD.
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.
• What are the most important R&D milestones and data publications to have happened in this disease area.

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1049123

Growth Of Global Schizoaffective Disorders Treatment Market During 2017 - 2022

Researchmoz added Most up-to-date research on "Growth Of Global Schizoaffective Disorders Treatment Market During 2017 - 2022" to its huge collection of research reports.

Presence of combination of two or more symptoms of schizophrenia such as delusions and hallucinations is referred as schizoaffective disorder condition. Schizoaffective disorders leads to deregulated emotions and abnormal thought process. Symptoms of Schizoaffective disorders include sudden changes in energy and appetite, disorganized and illogical speech, delusions, paranoia, delusions of reference, mood swings, lack of concentration, hallucinations, social isolation, non-stop speaking, difficulty in sleeping, sudden sadness and lack of grooming and hygiene concern.

Various blood tests such as complete blood count are performed to rule out the other conditions with similar symptoms. In addition to blood tests, imaging tests such as magnetic resonance imaging (MRI), electrocardiogram (ECG) and computed tomography (CT) are also used to eliminate other conditions with similar symptoms. Further, physicians recommend psychological evaluation for checking mental status by observing substance abuse, mood, and hallucinations. Based on the treatment, the global schizoaffective disorders treatment market is segmented as follows:

• Medicinal therapy
• Antipsychotics
• Clozapine
• Risperidone
• Haloperidol
• Olanzapine
• Others
• Mood stabilizers
• Lithium
• Divalproex
• Others
• Anticonvulsants

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=218862

Rapidly rising sedentary life style, prevalence of chronic diseases, increasing healthcare spending, availability of advanced healthcare treatments and increasing awareness about schizoaffective disorders are some of the factors that are driving the global schizoaffective disorders treatment market. While on the other hand, social stigma associated with schizoaffective disorders stringent regulatory approval procedures and lack of diagnosis at right time are some of the factors that are restraining the growth of the global schizoaffective disorders treatment market. 

Some of the key players in the global schizoaffective disorders treatment market include, Merz Pharma GmbH & Co. KGaA., Eli Lilliy and Company, Elan Pharmaceuticals, Ciba Pharmaceuticals, Abbott Pharmaceuticals, AstraZeneca plc, and Janssen-Cilag Pty Limited. 

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of 

• Market growth drivers 
• Factors limiting market growth
• Current market trends 
• Market structure
• Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth 
• It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
• It helps in understanding the key product segments and their future

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=218862